The recent reclassification of marijuana to a Schedule III drug has been touted as a significant step forward for research, but this enthusiasm is misguided. Despite the claims of supporters, the move does little to address the entrenched regulatory and infrastructure challenges that impede scientific progress. The focus should remain on prevention rather than legalisation, as this reclassification fails to resolve the broader public health issues associated with marijuana use.

For more details, visit: Axios.